278 related articles for article (PubMed ID: 24890740)
1. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
2. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
Supekar NT; Lakshminarayanan V; Capicciotti CJ; Sirohiwal A; Madsen CS; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2018 Jan; 19(2):121-125. PubMed ID: 29120508
[TBL] [Abstract][Full Text] [Related]
4. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
Wilkinson BL; Day S; Malins LR; Apostolopoulos V; Payne RJ
Angew Chem Int Ed Engl; 2011 Feb; 50(7):1635-9. PubMed ID: 21308921
[No Abstract] [Full Text] [Related]
5. Synthetic MUC1 Antitumor Vaccine Candidates with Varied Glycosylation Pattern Bearing R/S-configured Pam3 CysSerLys4.
Shi L; Cai H; Huang ZH; Sun ZY; Chen YX; Zhao YF; Kunz H; Li YM
Chembiochem; 2016 Aug; 17(15):1412-5. PubMed ID: 27188544
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
[TBL] [Abstract][Full Text] [Related]
7. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
Glaffig M; Stergiou N; Schmitt E; Kunz H
ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
[TBL] [Abstract][Full Text] [Related]
9. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
10. First self-adjuvant multicomponent potential vaccine candidates by tethering of four or eight MUC1 antigenic immunodominant PDTRP units on a calixarene platform: synthesis and biological evaluation.
Geraci C; Consoli GM; Granata G; Galante E; Palmigiano A; Pappalardo M; Di Puma SD; Spadaro A
Bioconjug Chem; 2013 Oct; 24(10):1710-20. PubMed ID: 24041198
[TBL] [Abstract][Full Text] [Related]
11. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
12. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
[TBL] [Abstract][Full Text] [Related]
14. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
Gaidzik N; Westerlind U; Kunz H
Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
Yin Z; Wu X; Kaczanowska K; Sungsuwan S; Comellas Aragones M; Pett C; Yu J; Baniel C; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2018 Jun; 13(6):1668-1676. PubMed ID: 29782143
[TBL] [Abstract][Full Text] [Related]
17. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.
Ingale S; Wolfert MA; Buskas T; Boons GJ
Chembiochem; 2009 Feb; 10(3):455-63. PubMed ID: 19145607
[TBL] [Abstract][Full Text] [Related]
18. Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.
Stergiou N; Gaidzik N; Heimes AS; Dietzen S; Besenius P; Jäkel J; Brenner W; Schmidt M; Kunz H; Schmitt E
Cancer Immunol Res; 2019 Jan; 7(1):113-122. PubMed ID: 30413430
[TBL] [Abstract][Full Text] [Related]
19. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
20. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]